
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novartis | Ruxolitinib | Jakavi | 2012-08-23 | $1,828 M | Q2/22-Q2/25 | |
| Bristol Myers Squibb | Fedratinib | Inrebic | 2021-02-08 | $110 M | Y2023 | |
| Endo | Sodium phenylbutyrate | Phenylbutyrate | 2016-06-15 |
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|